PHVS Pharvaris N.V.
Price Chart
Executive Summary
Pharvaris filed a prospectus supplement for an underwritten public offering of 3,874,664 ordinary shares at $29.68 per share, with an option for an additional 581,199 shares. The offering is expected to raise approximately $107.5 million in net proceeds (or $123.7 million if the option is fully exercised), which will be used to fund late-stage clinical programs, US commercialization efforts, and working capital. The company reported $247 million in cash as of March 31, 2026, and the offering extends its runway into the first half of 2028.
Actionable Insight
The offering is a routine capital raise for a pre-revenue biotech with positive Phase 3 data. Monitor the timing of the NDA submission and any updates on the XR tablet Phase 3 trial (CHAPTER-3). The modest dilution is offset by extended cash runway, but no near-term catalyst from this filing alone.
Key Facts
- Offering 3,874,664 shares at $29.68 per share, total gross proceeds of $115 million
- Underwriters have a 30-day option to purchase up to an additional 581,199 shares
- Net proceeds estimated at $107.5 million ($123.7 million with option exercise)
- Proceeds to fund R&D for late-stage programs, US commercialization, and working capital
- Cash and cash equivalents of approximately $247 million as of March 31, 2026
- Immediate dilution of $23.51 per share for new investors based on December 31, 2025 book value
- Shares outstanding will increase from 65,210,590 to up to 69,666,453 (if option exercised)
- Company plans to submit NDA for deucrictibant IR capsules in H1 2026
Financial Impact
Dilution of ~5.9% to existing shareholders; net proceeds of $107.5M extend runway into H1 2028
Risk Factors
- Immediate dilution of $23.51 per share for new investors
- No revenue, pre-commercial stage; reliance on regulatory approval
- Potential further dilution if additional capital is needed
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-214985 |
| Document: d36127dexfilingfees.htm | 0001193125-26-214985 |
| Document: 0001193125-26-214985-index-headers.html | 0001193125-26-214985 |
| Document: 0001193125-26-214985-index.html | 0001193125-26-214985 |
| Document: 0001193125-26-214985.txt | 0001193125-26-214985 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
16d ago
|
Press Release
| $30.16 $31.09 | ▲ +3.08% | ▲ +5.61% | $30.72 (+1.86%) |
|
May 26, 2026
19d ago
|
Insider Cluster
| $29.47 $30.14 | ▲ +2.27% | ▲ +1.80% | $30.72 (+4.24%) |
|
May 26, 2026
19d ago
|
Insider Cluster
| $29.47 $30.14 | ▼ −2.27% | ▼ −1.80% | $30.72 (−4.24%) |
|
May 22, 2026
23d ago
|
Insider Cluster
| $29.68 $29.10 | ▼ −1.95% | ▼ −3.63% | $30.72 (+3.50%) |
|
May 21, 2026
24d ago
|
144
| $29.68 $29.10 | ▼ −1.95% | ▼ −3.61% | $30.72 (+3.50%) |
|
May 20, 2026
25d ago
|
Insider Cluster
| $30.54 $30.16 | ▼ −1.24% | ▼ −3.09% | $30.72 (+0.59%) |
|
May 20, 2026
25d ago
|
144
| $30.54 $30.16 | ▼ −1.24% | ▼ −3.09% | $30.72 (+0.59%) |
|
May 19, 2026
26d ago
|
Insider Cluster
| $29.45 $29.86 | ▲ +1.39% | ▼ −0.41% | $30.72 (+4.31%) |
|
May 12, 2026
4w ago
|
Press Release
| $32.94 $28.95 | ▼ −12.11% | ▼ −10.95% | $30.72 (−6.74%) |
|
May 11, 2026
4w ago
|
6-K
| $31.25 $28.81 | ▼ −7.81% | ▼ −7.89% | $30.72 (−1.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access